<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Chris Kosmidis, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3478328095"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term 'chronic pulmonary aspergillosis' (CPA) encompasses several syndromes caused by the proliferation of <em>Aspergillus</em> organisms<em> </em>in the lungs of individuals with structural lung disease. CPA often remains unrecognized for prolonged periods and results in significant morbidity.</p><p>The epidemiology, clinical manifestations, and diagnosis of CPA will be reviewed here. The treatment of CPA is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2440.html" rel="external">"Chronic pulmonary aspergillosis: Treatment"</a>.)</p><p>Other forms of <em>Aspergillus</em>-associated disease include invasive aspergillosis (IA) and allergic bronchopulmonary aspergillosis (ABPA). Unlike CPA, IA exhibits extensive tissue invasion by the fungus and occurs in severely immunocompromised or critically ill individuals. ABPA is characterized by a chronic allergic response to <em>Aspergillus</em> antigens. Both IA and ABPA are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis"</a>.)</p><p class="headingAnchor" id="H1633439802"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Estimates of prevalence of CPA are inaccurate due to lack of surveillance and underdiagnosis of the disease. Based on modelling, an estimated worldwide prevalence of three million affected individuals has been reported [<a href="#rid1">1</a>]. Prevalence varies substantially by geography, with estimates of &lt;1 case per 100,000 persons in Western Europe and the United States to 43 cases per 100,000 persons in the Democratic Republic of Congo and Nigeria [<a href="#rid2">2</a>]. Because CPA can be a late sequela of tuberculosis (TB), the disease burden is higher in regions with a high incidence of TB [<a href="#rid2">2-8</a>].</p><p>All patients with CPA have a history of structural lung disease, often with residual cavities, bullae, or scarring. Specific risk factors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary TB – Worldwide, previously treated pulmonary TB is the most important risk factor [<a href="#rid9">9-12</a>]. An estimated 370,000 people developed CPA as a sequela of TB in 2007 [<a href="#rid2">2-8</a>]. Observational data suggest that TB accounts for over 85 percent of CPA cases in South and Southeast Asia, compared with 16 percent in the United Kingdom [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Approximately 20 to 35 percent of patients with resolved TB have residual pulmonary cavities that predispose to CPA, and the overall risk of developing an aspergilloma in a pulmonary cavity of over 2 cm in diameter has been estimated at 15 to 20 percent [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease (COPD), especially bullous disease [<a href="#rid12">12,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergic bronchopulmonary aspergillosis (ABPA) – In a United Kingdom series, seven percent of patients with ABPA had CPA in the form of aspergillomas [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nontuberculous mycobacteria (NTM) lung infection [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of thoracic surgery, especially for lung cancer [<a href="#rid17">17,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyper-IgE syndrome (ie, Job's syndrome). (See <a class="local">'Pathology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other conditions, including bronchiectasis, prior pneumothorax, COVID-19 infection, prior severe pneumonia, pneumoconiosis, silicosis, rheumatoid arthritis, ankylosing spondylitis, granulomatosis with polyangiitis, previous pulmonary embolism, and hydatid disease [<a href="#rid9">9,12,14,20-25</a>].</p><p></p><p class="bulletIndent1">Mild to moderate immunocompromise (eg, low-dose corticosteroids [eg, &lt; equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.3 mg/kg/day for &gt;3 weeks]) predisposes to a specific form of CPA called subacute invasive aspergillosis (SAIA), as discussed below. (See <a class="local">'Subacute invasive aspergillosis (SAIA)'</a> below.)</p><p></p><p class="headingAnchor" id="H2934148551"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span><em>Aspergillus fumigatus</em> (<em>A. fumigatus</em>) is the most common cause of CPA, although <em>A. flavus</em>, <em>A. niger</em>, <em>A. terreus</em>, and <em>A. nidulans</em> have also been implicated [<a href="#rid6">6,9,26-28</a>].</p><p>Aspergillomas may act as a niche for development of resistance, particularly in patients on prolonged antifungal therapy [<a href="#rid29">29</a>]. Resistance mutations vary geographically in patients with CPA; the most prominent mutation in India is the G54 mutation, whereas resistance in the United Kingdom is more commonly due to TR34/L98H and M220 [<a href="#rid30">30-33</a>]. Further details regarding <em>Aspergillus </em>resistance are found separately. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Consideration of antifungal resistance'</a>.)</p><p class="headingAnchor" id="H2542864479"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Current knowledge of the pathology of CPA comes from case series of surgically resected or post-mortem lesions, usually well-formed aspergillomas. CPA lesions of other types have not been as well characterized.</p><p>The primary driver of disease in patients with CPA is the local immune response to <em>Aspergillus </em>colonization of previously damaged lung tissue. Invasion of tissue by the fungus itself is not a major contributor to CPA in immunocompetent individuals. </p><p>In patients with CPA, the interplay between the fungal organisms and the patient's immune response determines the clinical and pathological presentation. Variable presentations have led to categorization of CPA into different syndromes.</p><p class="bulletIndent1"><span class="glyph">●</span>Two CPA syndromes (aspergillomas and <em>Aspergillus</em> nodules) are due to localized noninvasive proliferation of <em>Aspergillus</em> spp that do not elicit an extensive inflammatory response:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aspergillomas</strong> – Aspergillomas are formed when colonizing fungal organisms lining the inner surface of a pre-existing lung cavity spread into the cavity itself; the fungi proliferate in the form of a fungus ball inside the cavity. Microscopically, aspergillomas are composed of fungal hyphae, mucus, and cellular debris. Inflammation, if present, typically does not extend beyond the cavity wall. They are late manifestations of pre-existing persistent cavitary lung lesions. (See <a class="local">'Aspergilloma'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>Aspergillus </em></strong><strong>nodules</strong> – Nodules occur when the fungi replicate in a localized fashion in the lung parenchyma (unlike aspergillomas, which form inside of pre-existing cavities). Histopathologic evaluation reveals fungal hyphae, without evidence of tissue invasion, on a background of necrotic, fibrotic, and chronically inflamed lung tissue; granulomas are present in 25 percent of samples [<a href="#rid34">34,35</a>]. Nodules may have central cavitation due to necrosis. (See <a class="local">'Aspergillus nodule'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two additional forms of CPA are due to extensive tissue inflammation in response to <em>Aspergillus </em>colonization of previously damaged lungs. Actual fungal organisms are uncommonly found in affected lung tissue [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic cavitary pulmonary aspergillosis (CCPA)</strong> – This syndrome develops when chronic lung inflammation leads to parenchymal damage and expansion of one or more cavities that may or may not contain aspergillomas  (<a class="graphic graphic_diagnosticimage graphicRef141548" href="/z/d/graphic/141548.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef141549" href="/z/d/graphic/141549.html" rel="external">image 2</a>). CCPA may begin in pre-existing cavities, and/or cavities may be created as part of the disease process [<a href="#rid37">37</a>]. Histopathologic findings include erosion and granulation tissue in cavity walls with granuloma in some cases; tissue surrounding the cavities reveals florid chronic inflammation, sometimes with organizing pneumonia, bronchiectasis, hypertrophied blood vessels, and/or peri-cavitary fibrosis [<a href="#rid36">36,38</a>]. (See <a class="local">'Chronic cavitary pulmonary aspergillosis (CCPA)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic fibrosing pulmonary aspergillosis (CFPA)</strong> – This syndrome occurs in a subset of patients with CCPA. It is characterized by extensive parenchymal fibrosis surrounding CCPA cavities and sometimes in lung tissue distant from the cavities. (See <a class="local">'Chronic fibrosing pulmonary aspergillosis (CFPA)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute invasive aspergillosis (SAIA)</strong> – This is a unique form of CPA that has pathologic features that overlap with invasive aspergillosis (IA). Histopathology reveals necrotizing acute and chronic inflammation in combination with fungal hyphae invading lung tissue consistent with IA [<a href="#rid39">39</a>]. Destructive granulomatous destruction of bronchi and bronchioles (ie, bronchocentric granulomatosis) has also been described [<a href="#rid39">39</a>]. (See <a class="local">'Subacute invasive aspergillosis (SAIA)'</a> below.)</p><p></p><p>The importance of the immune system on the course of aspergillosis cannot be overstated. In immunocompetent patients with CPA, tissue invasion is absent and the clinical course is prolonged (months to years). For patients with SAIA and IA (all of whom have immunocompromise), tissue invasion is a key factor, and the clinical course is more rapidly progressive (weeks to months for SAIA, and days to weeks for IA). IA is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.) </p><p>Genetic defects in the Th1 inflammatory cascade have been identified in individuals with CPA, including reduced production of interferon-gamma upon stimulation of peripheral blood by fungal antigens [<a href="#rid40">40</a>]. Genetic analyses have also found other disorders of immune regulation such as polymorphisms in TLR3, TLR4, TLR10, the IL-1 pathway, and IL-15. CPA has also been reported in patients with known abnormalities of the JAK-STAT3 pathway associated with hyper-immunoglobulin (Ig)E syndrome (ie, Job's syndrome) [<a href="#rid41">41-45</a>].</p><p class="headingAnchor" id="H290095705"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2073921096"><span class="h2">Specific syndromes and radiographic features</span><span class="headingEndMark"> — </span>The term 'chronic pulmonary aspergillosis' (CPA) encompasses several syndromes that occur in individuals with pre-existing structural lung disease. In clinical practice, the syndromes and their radiographic features often overlap, and patients can transition from one form of CPA to another as their disease evolves over time.</p><p class="headingAnchor" id="H2928526000"><span class="h3">Aspergilloma</span><span class="headingEndMark"> — </span>Patients may have one or more aspergillomas.</p><p>The term 'simple aspergilloma' is used in patients with only one aspergilloma that is radiographically stable over time. Patients with a simple aspergilloma usually present with an incidental finding on radiographic imaging that was performed for another reason or for investigation of hemoptysis. Patients typically have no symptoms or have symptoms that are difficult to distinguish from those of their underlying lung disease. The most common symptom is cough. Hemoptysis may occur, including massive hemoptysis in a small subset of patients. Systemic symptoms (eg, fever, weight loss) do not occur in this form of CPA.</p><p>On radiographic imaging, an aspergilloma appears as a round, well-formed mass inside a pre-existing cavity, and it is often termed a 'fungus ball' or 'mycetoma' by radiologists  (<a class="graphic graphic_diagnosticimage graphicRef141544" href="/z/d/graphic/141544.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef141546" href="/z/d/graphic/141546.html" rel="external">image 4</a>). An aspergilloma sometimes has air pockets or calcification inside it, and it may be surrounded by air, have pockets or a crescent of air between them and the cavity wall, or have no surrounding air. An aspergilloma may be gravity dependent (ie, moves as the patient changes position) or immobile with strands connecting it to the wall of the cavity. Images obtained weeks to months prior to the discovery of an aspergilloma may reveal intracavitary fronds attached to the wall and extending into the cavity; subsequent imaging typically reveals that the fronds have coalesced and detached to form an aspergilloma. Imaging findings of aspergillomas are further discussed below. (See <a class="local">'Imaging suspicious for aspergilloma'</a> below.)</p><p>Some patients have multiple aspergillomas, a finding that is indicative of more symptomatic and destructive forms of CPA, as described elsewhere. (See <a class="local">'Chronic cavitary pulmonary aspergillosis (CCPA)'</a> below.)</p><p class="headingAnchor" id="H1116258067"><span class="h3">Aspergillus nodule</span><span class="headingEndMark"> — </span>Patients with <em>Aspergillus</em> nodules are typically asymptomatic and have undergone a percutaneous or excisional biopsy of a lung nodule to rule out malignancy. The diagnosis is made when the biopsied tissue reveals fungal hyphae consistent with <em>Aspergillus </em>spp on histology and no other etiology is identified.</p><p>The radiological appearance of an <em>Aspergillus</em> nodule cannot be reliably distinguished from nodules of other etiologies, including malignancy  (<a class="graphic graphic_diagnosticimage graphicRef141554" href="/z/d/graphic/141554.html" rel="external">image 5</a>) [<a href="#rid46">46</a>]. In a series of pathologically confirmed <em>Aspergillus</em> nodules, 20 percent were spiculated, 39 percent had calcification, and 61 percent were cavitary; the median long-axis diameter was 22 mm [<a href="#rid34">34</a>]. Patients may have single or multiple <em>Aspergillus</em> nodules.</p><p class="headingAnchor" id="H882838004"><span class="h3">Chronic cavitary pulmonary aspergillosis (CCPA)</span><span class="headingEndMark"> — </span>CCPA is the classic form of CPA; in practice, the terms CCPA and CPA are often used interchangeably. A principal feature of this syndrome is slow progression of both symptoms and radiographic findings over months to years.</p><p>Patients with CCPA present with symptoms of varying severity; some patients report minimal symptoms if identified early. However, symptoms eventually manifest as the disease progresses. Common symptoms include productive cough, hemoptysis, shortness of breath, chest pain, sweats, anorexia, weight loss, and fatigue; without treatment, weight loss and fatigue may be pronounced [<a href="#rid47">47-49</a>]. Fever is uncommon, except during concurrent bacterial or viral infection. Hemoptysis can range from blood-streaked sputum to massive fatal hemoptysis.</p><p>Radiographic imaging reveals one or more thick- or thin-walled cavities that often have irregular walls and intracavitary material; aspergillomas may develop within the cavities as the disease progresses  (<a class="graphic graphic_diagnosticimage graphicRef141544" href="/z/d/graphic/141544.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef141546" href="/z/d/graphic/141546.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef141552" href="/z/d/graphic/141552.html" rel="external">image 6</a> and <a class="graphic graphic_diagnosticimage graphicRef141550" href="/z/d/graphic/141550.html" rel="external">image 7</a>). The upper lobes are most commonly affected. As the disease progresses, new cavities develop or existing cavities expand, and they may coalesce or perforate into the pleural space  (<a class="graphic graphic_diagnosticimage graphicRef141546" href="/z/d/graphic/141546.html" rel="external">image 4</a>) [<a href="#rid36">36,38</a>].</p><p>Infiltrates are common surrounding the cavities. The thickness of cavity walls represents the inflammatory activity of the disease as well as possible adjacent fibrosis. For lesions close to the pleura, pleural thickening is very common. Concomitant findings include bronchiectasis, nodules, ground glass changes, tree-in-bud changes, and organizing pneumonia [<a href="#rid48">48</a>].</p><p>Pre-existing cavitary lung lesions are not necessary for the development of CCPA, but when present, these cavities can be the initial site of CCPA.</p><p class="headingAnchor" id="H3565199419"><span class="h3">Chronic fibrosing pulmonary aspergillosis (CFPA)</span><span class="headingEndMark"> — </span>CFPA occurs in a small subset of patients with CCPA and is characterized by extensive fibrosis and worsening lung function [<a href="#rid37">37</a>].</p><p>Patients with CFPA are typically already known to have CCPA, and the onset of CFPA is heralded by complaints of worsening shortness of breath, chest tightness, weight loss, and malnutrition [<a href="#rid50">50-52</a>].</p><p>Radiographic imaging typically reveals extensive pulmonary fibrosis in one or both upper lobes near the sites of known cavities and aspergillomas. In many cases, the fibrosis progresses to involve an entire lung, which can result in a 'white-out' of an entire lung or a 'destroyed lung' appearance  (<a class="graphic graphic_diagnosticimage graphicRef141547" href="/z/d/graphic/141547.html" rel="external">image 8</a>) [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2208602684"><span class="h3">Subacute invasive aspergillosis (SAIA)</span><span class="headingEndMark"> — </span>This term is reserved for patients who present with a subacute form of invasive aspergillosis (IA); SAIA progresses over one to three months as opposed to the more rapid presentation seen in patients with IA. Because of the slower nature of SAIA, it is categorized as a form of CPA instead of IA.</p><p>The features of SAIA straddle the line between IA and CPA. Symptoms are similar to those of CCPA except constitutional symptoms, including fever, are more prominent. Radiographic findings may include infiltrates, nodules, and consolidation with or without cavitation; the most common finding is a single area of consolidation  (<a class="graphic graphic_diagnosticimage graphicRef141553" href="/z/d/graphic/141553.html" rel="external">image 9</a>) [<a href="#rid37">37,50</a>]. Unlike other forms of CPA, pre-existing structural lung disease or cavitation is not necessary for the development of SAIA.</p><p>Because SAIA involves tissue invasion by the fungus and has a more rapid course than other forms of CPA, patients with SAIA are presumed to have some form of immunocompromise. In most patients, mild to moderate immunocompromise is known to be present (eg, poorly-controlled diabetes mellitus, prolonged low-dose corticosteroid therapy [eg,&lt; equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.3 mg/kg/day for &gt;3 weeks], advanced HIV disease, malnutrition) [<a href="#rid54">54</a>]. In a minority, underlying immunocompromising conditions are not identified but are presumed to be present. Patients with more severe underlying immunosuppression (eg, neutropenia, prolonged high-dose corticosteroid therapy) typically have IA as opposed to SAIA. Detailed discussion of IA is found separately. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p>Immunocompromised patients can also develop the other forms of CPA, characterized by a more chronic course and lack of tissue invasion (eg, aspergilloma, aspergillus nodule, CCPA). Furthermore, SAIA may evolve into other less progressive forms of CPA (eg, residual aspergilloma after treatment) over time.</p><p>SAIA was previously termed 'chronic necrotizing pulmonary aspergillosis' (CNPA) or 'semi-invasive pulmonary aspergillosis' (SIPA). </p><p class="headingAnchor" id="H2747602752"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory tests in patients with CPA often reflect the presence of chronic inflammation, with anemia of chronic disease, lymphopenia, hypoalbuminemia, elevated inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein), and polyclonal hypergammaglobulinemia. Laboratory findings are usually normal in patients with simple aspergillomas or <em>Aspergillus</em> nodules.</p><p>Microbiologic findings and diagnostic blood tests are discussed in detail below. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H3436150521"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The method of diagnosis of CPA depends on the specific syndrome suspected.</p><p class="headingAnchor" id="H930172242"><span class="h2">Limited value of microbiologic tests (eg, culture)</span><span class="headingEndMark"> — </span>Identification of <em>Aspergillus </em>spp (eg, by culture, visualization of hyphae, polymerase chain reaction [PCR]) from a respiratory specimen (eg, sputum, bronchial lavage fluid) is not diagnostic of any form of CPA, even in patients with compatible clinical and radiographic findings.</p><p><em>Aspergillus </em>spp are known to colonize the airways, and the majority of positive respiratory cultures in hospitalized patients represent colonization [<a href="#rid55">55-57</a>]. In patients with underlying lung pathology, differentiating colonization from CPA can be challenging because worsening of the underlying lung process can mimic symptoms and signs of CPA. Other processes, such as bacterial or mycobacterial infection, can also mimic CPA and be associated with <em>Aspergillus</em> colonization.</p><p>When <em>Aspergillus </em>spp are identified from a respiratory specimen, we clinically and radiographically evaluate the patient for signs of CPA. We send additional tests if we suspect CPA, as described below. (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p class="headingAnchor" id="H2032757808"><span class="h2">Patients with no or minimal symptoms</span><span class="headingEndMark"> — </span>Patients with CPA who have no or minimal symptoms, such as isolated hemoptysis, typically have a simple aspergilloma or an <em>Aspergillus</em> nodule.</p><p class="headingAnchor" id="H3215991981"><span class="h3">Imaging suspicious for aspergilloma</span><span class="headingEndMark"> — </span>Characteristic radiographic findings of an aspergilloma inside a pre-existing cavitary lung lesion allows for a presumptive diagnosis of an aspergilloma; it is rare for such radiographic findings to be due to any other cause. Details regarding imaging appearance of aspergillomas are found above. (See <a class="local">'Aspergilloma'</a> above.)</p><p>Patients with radiographic findings consistent with aspergilloma are characterized into one of two categories based on the number of cavities with an aspergilloma:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Simple aspergilloma</strong> – A presumptive diagnosis of a simple aspergilloma is made when radiography reveals a single aspergilloma inside a pre-existing cavitary lung lesion in a patient who has minimal symptoms (or any amount of hemoptysis). The cavity is usually thin-walled, round, and stable on serial imaging  (<a class="graphic graphic_diagnosticimage graphicRef141545" href="/z/d/graphic/141545.html" rel="external">image 10</a>).</p><p></p><p class="bulletIndent1">The diagnosis is confirmed with a positive serum<em> Aspergillus </em>IgG and documentation of stable or improved follow-up imaging obtained at least three months after the initial imaging [<a href="#rid37">37</a>]. (See <a class="local">'When to suspect chronic pulmonary aspergillosis'</a> below.)</p><p></p><p class="bulletIndent1"><em>Aspergillus</em> IgG is positive in over 90 percent of cases. If IgG is negative in a patient with high clinical suspicion who resides in an area where non-fumigatus strains are common (eg, Pakistan), additional testing should be performed which may include IgG testing for other species of <em>Aspergillus </em>[<a href="#rid58">58</a>]<em>. </em>Respiratory fluid (sputum or bronchoalveolar lavage [BAL]) and biopsy are not necessary to make this diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple cavities each containing an aspergilloma</strong> – Patients with this finding are typically symptomatic and are classified as having chronic cavitary pulmonary aspergillosis (CCPA), which is discussed in further detail elsewhere. (See <a class="local">'Chronic cavitary pulmonary aspergillosis (CCPA)'</a> above and <a class="local">'Symptomatic patients'</a> below.)</p><p></p><p class="headingAnchor" id="H2908939960"><span class="h3">Resected or biopsied Aspergillus nodule</span><span class="headingEndMark"> — </span>Definitive diagnosis of an <em>Aspergillus</em> nodule is made when lung tissue from a biopsy of a nodule is found to have fungal hyphae suggestive of <em>Aspergillus</em> on microscopic examination (see <a class="local">'Pathology'</a> above) [<a href="#rid37">37</a>]. A biopsy with histologic confirmation is always necessary because cancer may have a similar radiologic appearance.</p><p>In patients with multiple lung nodules including one that is a biopsy-confirmed <em>Aspergillus </em>nodule, the other nodules cannot be assumed to be <em>Aspergillus </em>nodules. Management of these patients varies on a case-by-case basis. Serial imaging is often helpful; follow-up with a pulmonologist, particularly for patients with risk factors for cancer (eg, smokers), may be beneficial.</p><p>Serum <em>Aspergillus</em> IgG may be positive or negative in patients with <em>Aspergillus</em> nodules; in a study of 24 patients with biopsy-confirmed <em>Aspergillus </em>nodules who had <em>Aspergillus </em>serology performed, 10 (42 percent) had negative serology [<a href="#rid34">34</a>]. Nonetheless, we typically obtain serology in our patients with <em>Aspergillus </em>nodules to establish a baseline value which may be helpful in situations where the nodule grows after biopsy.</p><p>In some cases, fungal organisms are not seen on histopathology but <em>Aspergillus </em>grows from tissue culture. These situations are challenging because the positive culture may represent contamination or colonization. We often follow these patients with serial imaging, and we repeat evaluation for malignancy, CPA, or other processes if changes occur.</p><p class="headingAnchor" id="H689647564"><span class="h2">Symptomatic patients</span><span class="headingEndMark"> — </span>In contrast with patients who have a simple aspergilloma or <em>Aspergillus</em> nodule, patients with other forms of CPA (ie, CCPA, CFPA, subacute invasive aspergillosis [SAIA]) have chronic progressive symptoms.</p><p class="headingAnchor" id="H1986118324"><span class="h3">When to suspect chronic pulmonary aspergillosis</span><span class="headingEndMark"> — </span>CCPA or CFPA should be suspected in individuals with a history of structural lung disease who have pulmonary and/or systemic symptoms and compatible radiographic findings (particularly lung cavities) that progress over months to years. (See <a class="local">'Chronic cavitary pulmonary aspergillosis (CCPA)'</a> above and <a class="local">'Chronic fibrosing pulmonary aspergillosis (CFPA)'</a> above.)</p><p>SAIA should be suspected if symptoms and radiologic findings progress over weeks to months in an individual with mild to moderate immunosuppression. (See <a class="local">'Subacute invasive aspergillosis (SAIA)'</a> above.)</p><p>In patients with hemoptysis, any form of CPA can be suspected, including simple aspergilloma, as noted above. (See <a class="local">'Aspergilloma'</a> above.)</p><p class="headingAnchor" id="H3991267898"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>For patients suspected of CCPA, CFPA, or SAIA, we obtain a computed tomography (CT) scan of the chest along with serologic testing. Microbiologic tests can play a supportive role.</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <em>Aspergillus</em> IgG – Although IgG is highly sensitive for the diagnosis of CCPA, IgG cannot confirm the diagnosis if radiologic and clinical findings are equivocal; alternative diagnoses may be present or coexist in a patient with a positive <em>Aspergillus</em> serology.</p><p></p><p class="bulletIndent1">When this test is ordered for patients who reside in areas where non-fumigatus strains are common (eg, Pakistan), separate IgG tests should be sent for <em>A. fumigatus </em>species and for the species predominant to the locale, if available<em> </em>[<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also perform the following tests, even though the sensitivity of these tests for these syndromes has not been systematically evaluated:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sputum for fungal stains and cultures, bacterial stains and cultures, and mycobacterial stains and cultures. Although <em>Aspergillus </em>spp can grow on standard bacterial culture plates, requesting the microbiology lab to perform dedicated fungal cultures increases the yield [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bronchoscopy with BAL for galactomannan testing, fungal stains and cultures, and PCR. We also send BAL fluid for bacterial stains and cultures, and mycobacterial stains and cultures, to assess for concomitant or alternative diagnoses. Biopsy is performed when a lesion that is suitable for biopsy is noted on a CT scan.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum for galactomannan testing. We do not send serum beta-D-glucan due to lack of data in patients with CPA and challenges with interpreting results [<a href="#rid27">27,60</a>].</p><p></p><p>For patients suspected of having an aspergilloma or <em>Aspergillus</em> nodule, the evaluation is discussed elsewhere. (See <a class="local">'Imaging suspicious for aspergilloma'</a> above and <a class="local">'Resected or biopsied Aspergillus nodule'</a> above.)</p><p class="headingAnchor" id="H449525396"><span class="h3">Confirming the diagnosis</span><span class="headingEndMark"> — </span>Definitive diagnosis of CPA cannot be established by a single test. Depending on the suspected syndrome, the diagnosis typically requires some combination of compatible clinical, radiographic, serologic, and microbiologic tests [<a href="#rid37">37</a>].</p><p>Each CPA syndrome has specific diagnostic criteria [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergillomas and </strong><strong><em>Aspergillus</em></strong><strong> nodules</strong> – The diagnostic criteria for these forms of CPA are discussed elsewhere. Most patients with these syndromes have no or minimal symptoms, although patients with a simple aspergilloma may have hemoptysis. (See <a class="local">'Imaging suspicious for aspergilloma'</a> above and <a class="local">'Resected or biopsied Aspergillus nodule'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic cavitary pulmonary aspergillosis (CCPA</strong>) – Definitive diagnosis of CCPA requires at least three months of compatible symptoms, characteristic radiographic findings with progression over at least three months, and positive serologic testing (ie, serum <em>Aspergillus</em> IgG) in the absence of an alternative diagnosis  (<a class="graphic graphic_diagnosticimage graphicRef141544" href="/z/d/graphic/141544.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef141546" href="/z/d/graphic/141546.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef141552" href="/z/d/graphic/141552.html" rel="external">image 6</a> and <a class="graphic graphic_diagnosticimage graphicRef141550" href="/z/d/graphic/141550.html" rel="external">image 7</a>) [<a href="#rid37">37</a>]. Microbiologic tests can support the diagnosis. (See <a class="local">'Chronic cavitary pulmonary aspergillosis (CCPA)'</a> above.)</p><p></p><p class="bulletIndent1">The contribution of various tests to the diagnosis of CCPA depends on the type of test:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood tests</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serum </strong><strong><em>Aspergillus</em></strong><strong> IgG</strong> – Serum IgG by enzyme immunoassay (EIA) is the lab test for diagnosing CCPA, and it is highly sensitive and specific in patients with characteristic clinical and radiographic findings. It can be very high in high-burden disease, such as CCPA with multiple or large aspergillomas. False-negative results may occur in patients with CCPA who reside in areas where non-fumigatus <em>Aspergillus</em> species are prevalent; in such patients, IgG tests that target the suspected non-fumigatus spp can be helpful, if available. Some institutions have developed in-house serologic tests using<em> Aspergillus </em>precipitin detection methods, but these tests may not be as sensitive or specific as IgG testing [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serum galactomannan </strong><strong><em>Aspergillus </em></strong><strong>antigen</strong> – This test can be helpful, but its sensitivity and specificity are suboptimal. In studies of CPA patients (most of whom had CCPA), sensitivity ranged from 40 to 64 percent using an index cut-off of &gt;0.5, and false-positive results occurred in substantial numbers of control patients [<a href="#rid27">27,28,60</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tests performed on respiratory fluids (eg, sputum, BAL fluid)</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Microbiologic tests</strong> – Fungal stains, fungal cultures, and molecular tests (eg, PCR) of respiratory fluid can provide supportive evidence of CCPA. Cultures are positive in 20 to 80 percent of respiratory samples (sputum or BAL fluid) from patients with CCPA, and positive cultures from BAL fluid are more likely to represent infection compared with positive sputum cultures [<a href="#rid37">37,60,62</a>]. Visualization of fungal hyphae in BAL fluid has been found to be highly suggestive of CCPA in patients with the appropriate clinical picture [<a href="#rid55">55</a>]. Available data suggest that PCR is more sensitive than culture, with sensitivities ranging from 71 to 87 percent when performed on BAL fluid, but this test is not standardized or available in all clinical settings [<a href="#rid33">33,60,63</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Galactomannan </strong><strong><em>Aspergillus </em></strong><strong>antigen</strong> – This test can be performed on BAL fluid. In case-control studies of patients with CPA (mostly CCPA), the positive predictive value ranged from 64 to 67 percent and the negative predictive value from 72 to 95 percent using a cut-off index of 0.5 [<a href="#rid27">27,60</a>]. The test should only be used on BAL fluid because it cannot differentiate colonization from infection in sputum samples from patients with CPA [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tissue biopsy</strong> – Biopsy is rarely performed to diagnose CCPA. Occasionally, CCPA diagnosis is made histologically with a transbronchial, CT-guided, or excisional biopsy in patients with severe hemoptysis or concern for cancer. Biopsied tissue, if obtained, should be sent for fungal stains, fungal cultures, and histopathology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic fibrosing pulmonary aspergillosis (CFPA)</strong> – CFPA is confirmed in patients who have known CCPA and develop extensive lung fibrosis on imaging, as described elsewhere  (<a class="graphic graphic_diagnosticimage graphicRef141547" href="/z/d/graphic/141547.html" rel="external">image 8</a>) (see <a class="local">'Chronic fibrosing pulmonary aspergillosis (CFPA)'</a> above). CFPA patients may have very high <em>Aspergillus</em> IgG titers [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute invasive aspergillosis (SAIA)</strong> – SAIA is confirmed in patients with evidence of invasive fungal disease on lung biopsy and a subacute course that lasts weeks to months, as opposed to the shorter course of acute invasive aspergillosis (IA). Mild to moderate immunocompromise is usually present and is presumed in patients with no known immunocompromising condition.</p><p></p><p class="bulletIndent1">However, in most patients with SAIA, biopsy is not performed. In these cases, a presumptive diagnosis of SAIA is based on:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A subacute presentation over one to three months (as opposed to the more acute presentation of IA)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Radiological findings compatible with SAIA: infiltrates, nodules, and consolidation with or without cavitation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild to moderate degree of immunocompromise</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence for the presence of <em>Aspergillus</em> in respiratory secretions (eg, positive fungal culture, galactomannan or <em>Aspergillus</em> PCR in BAL)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exclusion of alternative diagnoses</p><p></p><p class="bulletIndent1">Serum galactomannan and <em>Aspergillus </em>IgG are rarely positive in patients with SAIA [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">The diagnostic criteria for acute IA are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a>.)<strong> </strong></p><p></p><p class="headingAnchor" id="H4179128367"><span class="h2">Diagnosis in low-resource settings</span><span class="headingEndMark"> — </span>Because CPA can be a sequela of tuberculosis (TB), disproportionately more cases occur in low- to middle-income countries. Diagnostic capabilities may be limited, including lack of access to CT scan or <em>Aspergillus</em> IgG tests. In addition, the condition may not be suspected; it is often misdiagnosed as a TB relapse.</p><p>In these settings, a presumptive diagnosis can be made based on the presence of compatible symptoms for longer than three months, negative microbiologic TB tests, positive <em>Aspergillus</em> IgG, and the presence of cavitation on chest x-ray [<a href="#rid65">65</a>]. A point of care test for serum <em>Aspergillus</em> IgG is available and appears to be helpful in this setting [<a href="#rid3">3,66</a>].</p><p class="headingAnchor" id="H2819451919"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for CPA is broad and varies by syndrome. CPA must also be differentiated from invasive aspergillosis (IA) and allergic bronchopulmonary aspergillosis (ABPA).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive aspergillosis (IA)</strong> – IA has specific diagnostic criteria and involves patients who are severely immunocompromised (eg, neutropenia, high-dose corticosteroid therapy) or debilitated. (See  <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic bronchopulmonary aspergillosis (ABPA)</strong> – ABPA is associated with asthma and has a chronic waxing and waning course. Specific criteria exist for the diagnosis of ABPA. (See  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a>.)</p><p></p><p>The differential diagnosis for specific CPA syndromes includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergilloma</strong> – Characteristic clinical and radiographic findings are highly specific for aspergillomas, so the differential diagnosis is limited. The primary concern in a patient with an aspergilloma is the existence of an active concomitant process causing the underlying cavity. Such conditions include cavitary lung cancer, tuberculous (TB) and non-TB mycobacterial infections, and other fungal infections (eg, histoplasmosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, cryptococcosis). (See  <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/85894.html" rel="external">"Nontuberculous mycobacterial pulmonary infections in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Aspergillus</em></strong><strong> nodule</strong> – Any cause of lung nodules can mimic <em>Aspergillus</em> nodules, including carcinoma (eg, primary lung cancer, metastatic cancer). Tissue biopsy is necessary to differentiate these conditions. (See  <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">"Diagnostic evaluation of the incidental pulmonary nodule", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic cavitary pulmonary aspergillosis (CCPA), CFPA, and subacute invasive aspergillosis</strong> <strong>(SAIA)</strong> – Subacute progressive lung processes can mimic these forms of CPA. Infectious mimics include TB and non-TB mycobacterial infection, other fungal infection (eg, histoplasmosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, cryptococcosis), bacterial infection (eg, anaerobic infection, nocardiosis, <em>Rhodococcus </em>infection), and protozoal infection (eg, toxoplasmosis). Microbiologic and laboratory studies can confirm these diagnoses, and biopsy is necessary in some cases. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/85894.html" rel="external">"Nontuberculous mycobacterial pulmonary infections in children"</a> and  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a> and  <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">"Aspiration pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1">Noninfectious possibilities include sarcoidosis, pulmonary infarction, and ANCA-associated vasculitides and other autoimmune diseases (eg, rheumatoid arthritis). Tissue biopsy is often necessary to make these diagnoses, and serologic tests can be of value for the vasculitides and autoimmune diseases. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis"</a>.)</p><p></p><p class="headingAnchor" id="H3472381771"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology and risk factors</strong> – The term 'chronic pulmonary aspergillosis' (CPA) encompasses several syndromes (described below) caused by the proliferation of <em>Aspergillus</em> organisms<em> </em>in the lungs of individuals with structural lung disease. The most common risk factor is prior pulmonary tuberculosis (TB). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergilloma</strong> – An aspergilloma is a ball of <em>Aspergillus </em>fungi inside a pre-existing lung cavity. The term 'simple aspergilloma' is used in patients with only one aspergilloma that is radiographically stable over time. Most patients with simple aspergillomas are asymptomatic, although serious hemoptysis occurs in some cases. (See <a class="local">'Aspergilloma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – A presumptive diagnosis of an aspergilloma is made when radiography reveals a fungus ball inside a pre-existing cavitary lung lesion. The diagnosis is confirmed with a positive serum<em> Aspergillus </em>IgG and documentation of stable or improved follow-up imaging obtained at least three months after the initial imaging. (See <a class="local">'Imaging suspicious for aspergilloma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergillus nodule</strong> – An <em>Aspergillus </em>nodule is a lung nodule that reveals fungal hyphae consistent with <em>Aspergillus </em>on histology. Most <em>Aspergillus </em>nodules are initially biopsied or resected due to suspicion of malignancy. (See <a class="local">'Aspergillus nodule'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – Definitive diagnosis of an <em>Aspergillus</em> nodule is made when lung tissue from a biopsy of a nodule is found to have fungal hyphae suggestive of <em>Aspergillus</em> on microscopic examination. (See <a class="local">'Resected or biopsied Aspergillus nodule'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic cavitary pulmonary aspergillosis (CCPA)</strong> – This is the classic form of CPA and is characterized by slow progression of both symptoms and radiographic findings over months to years. A typical patient has a history of structural lung disease and productive cough, hemoptysis, shortness of breath, fatigue, and weight loss. (See <a class="local">'Chronic cavitary pulmonary aspergillosis (CCPA)'</a> above.)</p><p></p><p class="bulletIndent1">Radiographic findings include one or more cavities (that may or may not contain aspergillomas), infiltrates, and pleural thickening.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – Definitive diagnosis of CCPA requires at least three months of compatible symptoms, characteristic radiographic findings with progression over at least three months, and positive serologic testing (ie, serum <em>Aspergillus</em> IgG) in the absence of an alternative diagnosis. Microbiologic tests (eg, fungal culture or <em>Aspergillus </em>galactomannan tests) can support the diagnosis but are not definitive tests. (See <a class="local">'Confirming the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic fibrosing pulmonary aspergillosis (CFPA)</strong> – CFPA occurs in a small subset of patients with CCPA and is characterized by extensive fibrosis and worsening lung function that may eventually involve an entire lung. (See <a class="local">'Chronic fibrosing pulmonary aspergillosis (CFPA)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – CFPA is confirmed in patients who have known CCPA and develop extensive lung fibrosis on imaging. (See <a class="local">'Confirming the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute invasive aspergillosis (SAIA)</strong> – This term is reserved for patients who present with a subacute form of invasive aspergillosis (IA) that progresses over one to three months as opposed to the more rapid presentation seen in patients with acute IA.</p><p></p><p class="bulletIndent1">Most patients with SAIA have mild to moderate immunocompromise (eg, poorly-controlled diabetes mellitus, prolonged low-dose corticosteroid therapy). Unlike other forms of CPA, pre-existing structural lung disease or cavitation is not necessary. (See <a class="local">'Subacute invasive aspergillosis (SAIA)'</a> above.)</p><p></p><p class="bulletIndent1">Symptoms are similar to those of CCPA except constitutional symptoms, including fever, are more prominent. Radiographic findings may include infiltrates, nodules, and consolidation with or without cavitation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – SAIA is confirmed in patients with evidence of invasive fungal disease on lung biopsy and a subacute course that lasts weeks to months. (See <a class="local">'Confirming the diagnosis'</a> above.)</p><p></p><p class="bulletIndent2">However, in most patients with SAIA, biopsy is not performed. In these cases, a presumptive diagnosis of SAIA is based on:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A subacute presentation over one to three months</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Radiological findings compatible with SAIA</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mild to moderate immunocompromise</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Evidence for the presence of <em>Aspergillus</em> in respiratory secretions (eg, positive fungal culture, galactomannan or <em>Aspergillus</em> polymerase chain reaction [PCR] in bronchoalveolar lavage [BAL])</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Exclusion of alternative diagnoses</p><p></p><p class="bulletIndent2">Serum galactomannan and <em>Aspergillus </em>IgG are rarely positive in patients with SAIA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for CPA is broad and varies by syndrome. CPA must also be differentiated from IA and allergic bronchopulmonary aspergillosis (ABPA). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1848444641"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David Denning, MBBS, FRCP, FRCPath, FMedSci, who contributed to earlier versions of this topic review.</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zarif A, Thomas A, Vayro A. Chronic Pulmonary Aspergillosis: A Brief Review. Yale J Biol Med 2021; 94:673.</a></li><li><a class="nounderline abstract_t">Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011; 89:864.</a></li><li><a class="nounderline abstract_t">Rozaliyani A, Rosianawati H, Handayani D, et al. Chronic Pulmonary Aspergillosis in Post Tuberculosis Patients in Indonesia and the Role of LDBio Aspergillus ICT as Part of the Diagnosis Scheme. J Fungi (Basel) 2020; 6.</a></li><li><a class="nounderline abstract_t">Volpe-Chaves CE, Venturini J, B Castilho S, et al. Prevalence of chronic pulmonary aspergillosis regarding time of tuberculosis diagnosis in Brazil. Mycoses 2022; 65:715.</a></li><li><a class="nounderline abstract_t">Hedayati MT, Azimi Y, Droudinia A, et al. Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran. Eur J Clin Microbiol Infect Dis 2015; 34:1759.</a></li><li><a class="nounderline abstract_t">Ocansey BK, Otoo B, Adjei A, et al. Chronic pulmonary aspergillosis is common among patients with presumed tuberculosis relapse in Ghana. Med Mycol 2022; 60.</a></li><li><a class="nounderline abstract_t">Kim C, Moon JW, Park YB, Ko Y. Serological Changes in Anti-Aspergillus IgG Antibody and Development of Chronic Pulmonary Aspergillosis in Patients Treated for Pulmonary Tuberculosis. J Fungi (Basel) 2022; 8.</a></li><li><a class="nounderline abstract_t">Page ID, Byanyima R, Hosmane S, et al. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Iqbal N, Irfan M, Mushtaq A, Jabeen K. Underlying Conditions and Clinical Spectrum of Chronic Pulmonary Aspergillosis (CPA): An Experience from a Tertiary Care Hospital in Karachi, Pakistan. J Fungi (Basel) 2020; 6.</a></li><li><a class="nounderline abstract_t">Akram W, Ejaz MB, Mallhi TH, et al. Clinical manifestations, associated risk factors and treatment outcomes of Chronic Pulmonary Aspergillosis (CPA): Experiences from a tertiary care hospital in Lahore, Pakistan. PLoS One 2021; 16:e0259766.</a></li><li><a class="nounderline abstract_t">Nakamoto K, Takayanagi N, Kanauchi T, et al. Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med 2013; 52:727.</a></li><li><a class="nounderline abstract_t">Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37:865.</a></li><li><a class="nounderline abstract_t">Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax 2015; 70:270.</a></li><li><a class="nounderline abstract_t">Maitre T, Cottenet J, Godet C, et al. Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">McCarthy DS, Simon G, Hargreave FE. The radiological appearances in allergic broncho-pulmonary aspergillosis. Clin Radiol 1970; 21:366.</a></li><li><a class="nounderline abstract_t">Jhun BW, Jung WJ, Hwang NY, et al. Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease. PLoS One 2017; 12:e0188716.</a></li><li><a class="nounderline abstract_t">Tamura A, Suzuki J, Fukami T, et al. Chronic pulmonary aspergillosis as a sequel to lobectomy for lung cancer. Interact Cardiovasc Thorac Surg 2015; 21:650.</a></li><li><a class="nounderline abstract_t">Shin SH, Kim BG, Kang J, et al. Incidence and Risk Factors of Chronic Pulmonary Aspergillosis Development during Long-Term Follow-Up after Lung Cancer Surgery. J Fungi (Basel) 2020; 6.</a></li><li><a class="nounderline abstract_t">Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2013; 41:621.</a></li><li><a class="nounderline abstract_t">Emiralioğlu N, Özcan HN, Orhan D, et al. Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient after the surgery of hydatid cyst. Tuberk Toraks 2017; 65:157.</a></li><li><a class="nounderline abstract_t">Tunney R, Rodger K, Denning DW, Kosmidis C. Chronic pulmonary aspergillosis following pulmonary embolism. Med Mycol Case Rep 2019; 23:20.</a></li><li><a class="nounderline abstract_t">Danion F, Duréault A, Gautier C, et al. Emergence of azole resistant-Aspergillus fumigatus infections during STAT3-deficiency. J Med Microbiol 2020; 69:844.</a></li><li><a class="nounderline abstract_t">Eldaabossi S, Saad M, Alabdullah M, et al. Chronic Pulmonary Aspergillosis and Type 2 Diabetes Mellitus Complicating Granulomatosis with Polyangiitis in an Adult Saudi Male: A Case Report. Int Med Case Rep J 2021; 14:829.</a></li><li><a class="nounderline abstract_t">Horiuchi H, Utada S, Shinomiya Y, et al. Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases. Cureus 2022; 14:e27281.</a></li><li><a class="nounderline abstract_t">Chaurasia S, Thimmappa M, Chowdhury S. Case Report: Chronic Cavitatory Pulmonary Aspergillosis after COVID-19. Am J Trop Med Hyg 2021; 106:105.</a></li><li><a class="nounderline abstract_t">Aguilar-Company J, Martín MT, Goterris-Bonet L, et al. Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study. Mycoses 2019; 62:765.</a></li><li><a class="nounderline abstract_t">Takazono T, Ito Y, Tashiro M, et al. Evaluation of Aspergillus-Specific Lateral-Flow Device Test Using Serum and Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Sehgal IS, Dhooria S, Choudhary H, et al. Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Howard SJ, Pasqualotto AC, Anderson MJ, et al. Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses 2013; 56:434.</a></li><li><a class="nounderline abstract_t">Bongomin F, Harris C, Hayes G, et al. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One 2018; 13:e0193732.</a></li><li><a class="nounderline abstract_t">Takeda K, Suzuki J, Watanabe A, et al. High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance. Med Mycol 2021; 59:327.</a></li><li><a class="nounderline abstract_t">Singh A, Sharma B, Mahto KK, et al. High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India. J Fungi (Basel) 2020; 6.</a></li><li><a class="nounderline abstract_t">Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52:1123.</a></li><li><a class="nounderline abstract_t">Kang N, Park J, Jhun BW. Clinical Characteristics and Treatment Outcomes of Pathologically Confirmed Aspergillus Nodules. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Muldoon EG, Sharman A, Page I, et al. Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis. BMC Pulm Med 2016; 16:123.</a></li><li><a class="nounderline abstract_t">Tochigi N, Ishiwatari T, Okubo Y, et al. Histological study of chronic pulmonary aspergillosis. Diagn Pathol 2015; 10:153.</a></li><li><a class="nounderline abstract_t">Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47:45.</a></li><li><a class="nounderline abstract_t">Ando T, Tochigi N, Gocho K, et al. Pathophysiological Implication of Computed Tomography Images of Chronic Pulmonary Aspergillosis. Jpn J Infect Dis 2016; 69:118.</a></li><li><a class="nounderline abstract_t">Yousem SA. The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol 1997; 28:650.</a></li><li><a class="nounderline abstract_t">Colombo SAP, Hashad R, Denning DW, et al. Defective Interferon-Gamma Production Is Common in Chronic Pulmonary Aspergillosis. J Infect Dis 2022; 225:1822.</a></li><li><a class="nounderline abstract_t">Smith NL, Hankinson J, Simpson A, et al. Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. Clin Microbiol Infect 2014; 20:O960.</a></li><li><a class="nounderline abstract_t">Smith NL, Hankinson J, Simpson A, et al. A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. Clin Microbiol Infect 2014; 20:O480.</a></li><li><a class="nounderline abstract_t">Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008; 197:618.</a></li><li><a class="nounderline abstract_t">Duréault A, Tcherakian C, Poiree S, et al. Spectrum of Pulmonary Aspergillosis in Hyper-IgE Syndrome with Autosomal-Dominant STAT3 Deficiency. J Allergy Clin Immunol Pract 2019; 7:1986.</a></li><li><a class="nounderline abstract_t">da Silva-Ferreira S, Duarte-Oliveira C, Antunes D, et al. Hypoxia inducible-factor 1 alpha regulates neutrophil recruitment during fungal-elicited granulomatous inflammation. Front Cell Infect Microbiol 2022; 12:1005839.</a></li><li><a class="nounderline abstract_t">Rønberg R, Davidsen JR, Salzer HJF, et al. Prevalence of Chronic Pulmonary Aspergillosis in Patients Suspected of Chest Malignancy. J Fungi (Basel) 2022; 8.</a></li><li><a class="nounderline abstract_t">Hou X, Zhang H, Kou L, et al. Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients. Medicine (Baltimore) 2017; 96:e8315.</a></li><li><a class="nounderline abstract_t">Godet C, Laurent F, Bergeron A, et al. CT Imaging Assessment of Response to Treatment in Chronic Pulmonary Aspergillosis. Chest 2016; 150:139.</a></li><li><a class="nounderline abstract_t">Al-Shair K, Muldoon EG, Morris J, et al. Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA). Respir Med 2016; 114:117.</a></li><li><a class="nounderline abstract_t">Izumikawa K, Tashiro T, Tashiro M, et al. Pathogenesis and clinical features of chronic pulmonary aspergillosis - is it possible to distinguish CNPA and CCPA clinically? J Infect Chemother 2014; 20:208.</a></li><li><a class="nounderline abstract_t">Zhong H, Wang Y, Gu Y, et al. Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis. Front Med (Lausanne) 2022; 9:811807.</a></li><li><a class="nounderline abstract_t">Despois O, Chen SC, Gilroy N, et al. Chronic Pulmonary Aspergillosis: Burden, Clinical Characteristics and Treatment Outcomes at a Large Australian Tertiary Hospital. J Fungi (Basel) 2022; 8.</a></li><li><a class="nounderline abstract_t">Kosmidis C, Newton P, Muldoon EG, Denning DW. Chronic fibrosing pulmonary aspergillosis: a cause of 'destroyed lung' syndrome. Infect Dis (Lond) 2017; 49:296.</a></li><li><a class="nounderline abstract_t">Denning DW, Morgan EF. Quantifying Deaths from Aspergillosis in HIV Positive People. J Fungi (Basel) 2022; 8.</a></li><li><a class="nounderline abstract_t">Uffredi ML, Mangiapan G, Cadranel J, Kac G. Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 2003; 22:457.</a></li><li><a class="nounderline abstract_t">El-Baba F, Watza D, Soubani AO. Is Aspergillus isolated from respiratory cultures clinically significant? Cleve Clin J Med 2021; 88:543.</a></li><li><a class="nounderline abstract_t">Soubani AO, Khanchandani G, Ahmed HP. Clinical significance of lower respiratory tract Aspergillus culture in elderly hospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23:491.</a></li><li><a class="nounderline abstract_t">Jabeen K, Farooqi J, Iqbal N, et al. Aspergillus fumigatus and Aspergillus flavus-Specific IgG Cut-Offs for the Diagnosis of Chronic Pulmonary Aspergillosis in Pakistan. J Fungi (Basel) 2020; 6.</a></li><li><a class="nounderline abstract_t">Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100:171.</a></li><li><a class="nounderline abstract_t">Urabe N, Sakamoto S, Sano G, et al. Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β-d-Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis. J Clin Microbiol 2017; 55:1738.</a></li><li><a class="nounderline abstract_t">Page ID, Richardson MD, Denning DW. Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). J Infect 2016; 72:240.</a></li><li><a class="nounderline abstract_t">Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 Suppl 3:S265.</a></li><li><a class="nounderline abstract_t">Denning DW, Perlin DS. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol 2011; 6:1229.</a></li><li><a class="nounderline abstract_t">Nuh A, Ramadan N, Shah A, Armstrong-James D. Sputum Galactomannan Has Utility in the Diagnosis of Chronic Pulmonary Aspergillosis. J Fungi (Basel) 2022; 8.</a></li><li><a class="nounderline abstract_t">Denning DW, Page ID, Chakaya J, et al. Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. Emerg Infect Dis 2018; 24.</a></li><li><a class="nounderline abstract_t">Stucky Hunter E, Richardson MD, Denning DW. Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis. J Clin Microbiol 2019; 57.</a></li></ol></div><div id="topicVersionRevision">Topic 2441 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34970105" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic Pulmonary Aspergillosis: A Brief Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271943" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33260909" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic Pulmonary Aspergillosis in Post Tuberculosis Patients in Indonesia and the Role of LDBio Aspergillus ICT as Part of the Diagnosis Scheme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35524507" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of chronic pulmonary aspergillosis regarding time of tuberculosis diagnosis in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26003310" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35953428" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronic pulmonary aspergillosis is common among patients with presumed tuberculosis relapse in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35205886" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Serological Changes in Anti-Aspergillus IgG Antibody and Development of Chronic Pulmonary Aspergillosis in Patients Treated for Pulmonary Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30705126" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32225054" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Underlying Conditions and Clinical Spectrum of Chronic Pulmonary Aspergillosis (CPA): An Experience from a Tertiary Care Hospital in Karachi, Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34767589" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical manifestations, associated risk factors and treatment outcomes of Chronic Pulmonary Aspergillosis (CPA): Experiences from a tertiary care hospital in Lahore, Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545666" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595150" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25354514" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The clinical spectrum of pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33479108" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5476800" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The radiological appearances in allergic broncho-pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29190796" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323287" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chronic pulmonary aspergillosis as a sequel to lobectomy for lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33182358" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence and Risk Factors of Chronic Pulmonary Aspergillosis Development during Long-Term Follow-Up after Lung Cancer Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22743676" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Global burden of chronic pulmonary aspergillosis complicating sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28990897" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient after the surgery of hydatid cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30505676" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chronic pulmonary aspergillosis following pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459615" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Emergence of azole resistant-Aspergillus fumigatus infections during STAT3-deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34984031" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chronic Pulmonary Aspergillosis and Type 2 Diabetes Mellitus Complicating Granulomatosis with Polyangiitis in an Adult Saudi Male: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36039212" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chronic Pulmonary Aspergillosis During Convalescence From Severe COVID-19 Treated With Oral Itraconazole: A Report of Two Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34818624" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Case Report: Chronic Cavitatory Pulmonary Aspergillosis after COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162731" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30842231" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Evaluation of Aspergillus-Specific Lateral-Flow Device Test Using Serum and Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30626661" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23369025" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29634721" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32642756" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443672" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467016" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32664449" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical Characteristics and Treatment Outcomes of Pathologically Confirmed Aspergillus Nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27538521" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26334307" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Histological study of chronic pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26699723" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26166500" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pathophysiological Implication of Computed Tomography Images of Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9190998" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850023" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Defective Interferon-Gamma Production Is Common in Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24712925" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24274595" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18275280" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30878710" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Spectrum of Pulmonary Aspergillosis in Hyper-IgE Syndrome with Autosomal-Dominant STAT3 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36275017" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hypoxia inducible-factor 1 alpha regulates neutrophil recruitment during fungal-elicited granulomatous inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35330299" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prevalence of Chronic Pulmonary Aspergillosis in Patients Suspected of Chest Malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049239" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26905365" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : CT Imaging Assessment of Response to Treatment in Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27109821" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477329" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pathogenesis and clinical features of chronic pulmonary aspergillosis - is it possible to distinguish CNPA and CCPA clinically?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35223906" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35205864" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chronic Pulmonary Aspergillosis: Burden, Clinical Characteristics and Treatment Outcomes at a Large Australian Tertiary Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27658458" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chronic fibrosing pulmonary aspergillosis: a cause of 'destroyed lung' syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36354898" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Quantifying Deaths from Aspergillosis in HIV Positive People.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12898283" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34598918" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Is Aspergillus isolated from respiratory cultures clinically significant?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15141337" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical significance of lower respiratory tract Aspergillus culture in elderly hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33114653" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Aspergillus fumigatus and Aspergillus flavus-Specific IgG Cut-Offs for the Diagnosis of Chronic Pulmonary Aspergillosis in Pakistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629651" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28330887" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan andβ-d-Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26680697" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975754" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082283" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Azole resistance in Aspergillus: a growing public health menace.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35205942" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sputum Galactomannan Has Utility in the Diagnosis of Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30016256" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31217272" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
